Brokerages expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to announce ($1.74) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Agios Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.79) and the highest is ($1.67). Agios Pharmaceuticals reported earnings per share of ($1.63) in the same quarter last year, which suggests a negative year-over-year growth rate of 6.7%. The business is scheduled to announce its next quarterly earnings results on Friday, May 3rd.
On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.73) per share for the current fiscal year, with EPS estimates ranging from ($7.41) to ($6.06). For the next year, analysts anticipate that the company will report earnings of ($6.32) per share, with EPS estimates ranging from ($7.25) to ($4.94). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.65) by $0.07. The firm had revenue of $30.00 million for the quarter, compared to analyst estimates of $19.98 million. Agios Pharmaceuticals had a negative return on equity of 44.13% and a negative net margin of 366.61%. The business’s revenue for the quarter was up 200.0% on a year-over-year basis. During the same period last year, the firm posted ($1.81) earnings per share.
In other news, insider Scott Biller sold 9,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $65.00, for a total transaction of $585,000.00. Following the completion of the sale, the insider now owns 28,277 shares in the company, valued at $1,838,005. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Steven L. Hoerter sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $67.01, for a total value of $670,100.00. Following the sale, the insider now owns 26,939 shares of the company’s stock, valued at approximately $1,805,182.39. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $1,896,700. Corporate insiders own 3.02% of the company’s stock.
A number of institutional investors have recently made changes to their positions in AGIO. Quantamental Technologies LLC bought a new stake in Agios Pharmaceuticals during the fourth quarter worth $28,000. Advisor Group Inc. lifted its position in shares of Agios Pharmaceuticals by 33.1% during the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 297 shares during the last quarter. ETF Managers Group LLC lifted its position in shares of Agios Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 216 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Agios Pharmaceuticals by 14.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 430 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $188,000. Institutional investors and hedge funds own 98.44% of the company’s stock.
Shares of Agios Pharmaceuticals stock traded up $2.00 during midday trading on Friday, reaching $67.44. The company had a trading volume of 612,967 shares, compared to its average volume of 416,000. The firm has a market cap of $3.82 billion, a P/E ratio of -11.18 and a beta of 2.38. Agios Pharmaceuticals has a fifty-two week low of $41.63 and a fifty-two week high of $99.82.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Featured Article: What is the balance sheet?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.